[go: up one dir, main page]

MX2021001554A - Metodo de preparacion de una formulacion farmaceutica de anticuerpos. - Google Patents

Metodo de preparacion de una formulacion farmaceutica de anticuerpos.

Info

Publication number
MX2021001554A
MX2021001554A MX2021001554A MX2021001554A MX2021001554A MX 2021001554 A MX2021001554 A MX 2021001554A MX 2021001554 A MX2021001554 A MX 2021001554A MX 2021001554 A MX2021001554 A MX 2021001554A MX 2021001554 A MX2021001554 A MX 2021001554A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
preparation
antibody pharmaceutical
antibody
antigen
Prior art date
Application number
MX2021001554A
Other languages
English (en)
Inventor
Ashutosh Sharma
Bryan Dransart
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021001554A publication Critical patent/MX2021001554A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona materiales y métodos para preparar una formulación farmacéutica de anticuerpos que tiene una viscosidad de 10 cP o menos que comprende intercambiar una composición que comprende la proteína de unión a antígeno por un tampón de diafiltración que comprende calcio a una temperatura mayor de 30°C.
MX2021001554A 2018-08-10 2019-08-09 Metodo de preparacion de una formulacion farmaceutica de anticuerpos. MX2021001554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862717357P 2018-08-10 2018-08-10
PCT/US2019/045836 WO2020033788A1 (en) 2018-08-10 2019-08-09 Method of preparing an antibody pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2021001554A true MX2021001554A (es) 2021-04-13

Family

ID=67734839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001554A MX2021001554A (es) 2018-08-10 2019-08-09 Metodo de preparacion de una formulacion farmaceutica de anticuerpos.

Country Status (14)

Country Link
US (2) US20210308265A1 (es)
EP (1) EP3833327A1 (es)
JP (2) JP7425041B2 (es)
KR (1) KR20210043607A (es)
CN (1) CN112702991A (es)
AU (1) AU2019316575B2 (es)
BR (1) BR112021002506A2 (es)
CA (1) CA3108693A1 (es)
EA (1) EA202190482A1 (es)
IL (1) IL280642B1 (es)
MA (1) MA53272A (es)
MX (1) MX2021001554A (es)
SG (1) SG11202100952QA (es)
WO (1) WO2020033788A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1391707A (en) 1918-08-15 1921-09-27 Viviano Philip Automatic change-speed transmission
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006330858A1 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2008092894A1 (en) 2007-02-02 2008-08-07 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
MX2009010051A (es) 2007-03-20 2009-10-12 Lilly Co Eli Anticuerpos anti-esclereostina.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
JP5764329B2 (ja) 2007-11-02 2015-08-19 ノバルティス アーゲー 低比重リポタンパク質受容体関連タンパク質６（ｌｒｐ６）を調節するための分子および方法
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP3240571A4 (en) * 2014-12-31 2018-06-13 NovelMed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation

Also Published As

Publication number Publication date
US20210308265A1 (en) 2021-10-07
IL280642A (en) 2021-03-25
US20240342288A1 (en) 2024-10-17
BR112021002506A2 (pt) 2021-07-27
EP3833327A1 (en) 2021-06-16
JP7425041B2 (ja) 2024-01-30
JP2021534117A (ja) 2021-12-09
AU2019316575A1 (en) 2021-03-04
MA53272A (fr) 2021-11-17
SG11202100952QA (en) 2021-02-25
KR20210043607A (ko) 2021-04-21
EA202190482A1 (ru) 2021-05-25
JP2024045250A (ja) 2024-04-02
AU2019316575B2 (en) 2025-05-22
CN112702991A (zh) 2021-04-23
CA3108693A1 (en) 2020-02-13
WO2020033788A1 (en) 2020-02-13
IL280642B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
BR112018076281A2 (pt) imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
CL2019003032A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas.
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CL2019003627A1 (es) Anticuerpos anti-pd-1 y sus usos. (solicitud divisional 201900628)
EP3866924A4 (en) COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
CL2020001391A1 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina.
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
BR112017027778A2 (pt) anticorpos para o fator xi e métodos de uso
BR112015025306A2 (pt) anticorpo biespecífico, anticorpos, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira procariótica ou eucariótica e método de produção de um anticorpo
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112017013661A2 (pt) conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112016026811A2 (pt) formulação de anticorpo
MX2021011956A (es) Metodos y composiciones para la insercion de secuencias codificantes de anticuerpos en un locus de puerto seguro.
BR112021026414A2 (pt) Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
JOP20190189A1 (ar) تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
BR112019023846A2 (pt) composição farmacêutica de anticorpo de pd-l1 e uso da mesma
CL2020003277A1 (es) Métodos de fabricación de composiciones de aminoácidos
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
BR112016015078A2 (pt) método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica
BR112018008840A8 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2021001554A (es) Metodo de preparacion de una formulacion farmaceutica de anticuerpos.
BR112019002852A2 (pt) anticorpo anti-pd-l1
EP3873942A4 (en) Compositions and methods comprising iga antibody constructs